[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

United States Renal Cell Cacinoma Drugs Market Report 2017

November 2017 | 112 pages | ID: U0170EE95E2WEN
QYResearch

US$ 3,800.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
In this report, the United States Renal Cell Cacinoma Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
  • The West
  • Southwest
  • The Middle Atlantic
  • New England
  • The South
  • The Midwest
  • with sales (volume), revenue (value), market share and growth rate of Renal Cell Cacinoma Drugs in these regions, from 2012 to 2022 (forecast).
United States Renal Cell Cacinoma Drugs market competition by top manufacturers/players, with Renal Cell Cacinoma Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
  • Merck & Co., Inc.
  • Exelixis Inc
  • Argus Therapeutics, Inc.
  • Bristol-Myers Squibb
  • Genentech
  • Immatics Biotechnologies
  • AVEO Oncology
  • Eisai
  • Acceleron
  • Rexahn Pharmaceuticals
  • Bionomics
  • Cerulean Pharma Inc
  • Celldex Therapeutics
  • TVAX Biomedical
  • TRACON Pharmaceuticals
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
  • Sutent(Sunitinib)
  • Nexavar(Sorafenib)
  • Votrient(Pazopanib)
  • Avastin(Bevacizumab)
  • Afinitor(Everolimus)
  • Inlyta(Axitinib)
  • Torisel(Temsirolimus)
  • Proleukin(Aldesleukin)
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
  • Mucinous Tubular and Spindle Cell Carcinoma (MTSCC)
  • Multilocular Cystic Clear Cell Renal Cell Carcinoma
  • Tubulocystic Renal Cell Carcinoma
  • Thyroid-Like Follicular Renal Cell Carcinoma
  • Others
If you have any special requirements, please let us know and we will offer you the report as you want.
United States Renal Cell Cacinoma Drugs Market Report 2017

1 RENAL CELL CACINOMA DRUGS OVERVIEW

1.1 Product Overview and Scope of Renal Cell Cacinoma Drugs
1.2 Classification of Renal Cell Cacinoma Drugs by Product Category
  1.2.1 United States Renal Cell Cacinoma Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Renal Cell Cacinoma Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Sutent(Sunitinib)
  1.2.4 Nexavar(Sorafenib)
  1.2.5 Votrient(Pazopanib)
  1.2.6 Avastin(Bevacizumab)
  1.2.7 Afinitor(Everolimus)
  1.2.8 Inlyta(Axitinib)
  1.2.9 Torisel(Temsirolimus)
  1.2.10 Proleukin(Aldesleukin)
1.3 United States Renal Cell Cacinoma Drugs Market by Application/End Users
  1.3.1 United States Renal Cell Cacinoma Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Mucinous Tubular and Spindle Cell Carcinoma (MTSCC)
  1.3.3 Multilocular Cystic Clear Cell Renal Cell Carcinoma
  1.3.4 Tubulocystic Renal Cell Carcinoma
  1.3.5 Thyroid-Like Follicular Renal Cell Carcinoma
  1.3.6 Others
1.4 United States Renal Cell Cacinoma Drugs Market by Region
  1.4.1 United States Renal Cell Cacinoma Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Renal Cell Cacinoma Drugs Status and Prospect (2012-2022)
  1.4.3 Southwest Renal Cell Cacinoma Drugs Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Renal Cell Cacinoma Drugs Status and Prospect (2012-2022)
  1.4.5 New England Renal Cell Cacinoma Drugs Status and Prospect (2012-2022)
  1.4.6 The South Renal Cell Cacinoma Drugs Status and Prospect (2012-2022)
  1.4.7 The Midwest Renal Cell Cacinoma Drugs Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Renal Cell Cacinoma Drugs (2012-2022)
  1.5.1 United States Renal Cell Cacinoma Drugs Sales and Growth Rate (2012-2022)
  1.5.2 United States Renal Cell Cacinoma Drugs Revenue and Growth Rate (2012-2022)

2 UNITED STATES RENAL CELL CACINOMA DRUGS MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Renal Cell Cacinoma Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Renal Cell Cacinoma Drugs Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Renal Cell Cacinoma Drugs Average Price by Players/Suppliers (2012-2017)
2.4 United States Renal Cell Cacinoma Drugs Market Competitive Situation and Trends
  2.4.1 United States Renal Cell Cacinoma Drugs Market Concentration Rate
  2.4.2 United States Renal Cell Cacinoma Drugs Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Renal Cell Cacinoma Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES RENAL CELL CACINOMA DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Renal Cell Cacinoma Drugs Sales and Market Share by Region (2012-2017)
3.2 United States Renal Cell Cacinoma Drugs Revenue and Market Share by Region (2012-2017)
3.3 United States Renal Cell Cacinoma Drugs Price by Region (2012-2017)

4 UNITED STATES RENAL CELL CACINOMA DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Renal Cell Cacinoma Drugs Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Renal Cell Cacinoma Drugs Revenue and Market Share by Type (2012-2017)
4.3 United States Renal Cell Cacinoma Drugs Price by Type (2012-2017)
4.4 United States Renal Cell Cacinoma Drugs Sales Growth Rate by Type (2012-2017)

5 UNITED STATES RENAL CELL CACINOMA DRUGS SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Renal Cell Cacinoma Drugs Sales and Market Share by Application (2012-2017)
5.2 United States Renal Cell Cacinoma Drugs Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES RENAL CELL CACINOMA DRUGS PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Merck & Co., Inc.
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Merck & Co., Inc. Renal Cell Cacinoma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Exelixis Inc
  6.2.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Exelixis Inc Renal Cell Cacinoma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Argus Therapeutics, Inc.
  6.3.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Argus Therapeutics, Inc. Renal Cell Cacinoma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Bristol-Myers Squibb
  6.4.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Bristol-Myers Squibb Renal Cell Cacinoma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Genentech
  6.5.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Genentech Renal Cell Cacinoma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Immatics Biotechnologies
  6.6.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Immatics Biotechnologies Renal Cell Cacinoma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 AVEO Oncology
  6.7.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 AVEO Oncology Renal Cell Cacinoma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Eisai
  6.8.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Eisai Renal Cell Cacinoma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Acceleron
  6.9.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Acceleron Renal Cell Cacinoma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Rexahn Pharmaceuticals
  6.10.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Rexahn Pharmaceuticals Renal Cell Cacinoma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 Bionomics
6.12 Cerulean Pharma Inc
6.13 Celldex Therapeutics
6.14 TVAX Biomedical
6.15 TRACON Pharmaceuticals

7 RENAL CELL CACINOMA DRUGS MANUFACTURING COST ANALYSIS

7.1 Renal Cell Cacinoma Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Renal Cell Cacinoma Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Renal Cell Cacinoma Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Renal Cell Cacinoma Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES RENAL CELL CACINOMA DRUGS MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Renal Cell Cacinoma Drugs Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Renal Cell Cacinoma Drugs Sales Volume Forecast by Type (2017-2022)
11.3 United States Renal Cell Cacinoma Drugs Sales Volume Forecast by Application (2017-2022)
11.4 United States Renal Cell Cacinoma Drugs Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.


LIST OF TABLES AND FIGURES

Figure Product Picture of Renal Cell Cacinoma Drugs
Figure United States Renal Cell Cacinoma Drugs Market Size (K Pcs) by Type (2012-2022)
Figure United States Renal Cell Cacinoma Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Sutent(Sunitinib) Product Picture
Figure Nexavar(Sorafenib) Product Picture
Figure Votrient(Pazopanib) Product Picture
Figure Avastin(Bevacizumab) Product Picture
Figure Afinitor(Everolimus) Product Picture
Figure Inlyta(Axitinib) Product Picture
Figure Torisel(Temsirolimus) Product Picture
Figure Proleukin(Aldesleukin) Product Picture
Figure United States Renal Cell Cacinoma Drugs Market Size (K Pcs) by Application (2012-2022)
Figure United States Sales Market Share of Renal Cell Cacinoma Drugs by Application in 2016
Figure Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) Examples
Table Key Downstream Customer in Mucinous Tubular and Spindle Cell Carcinoma (MTSCC)
Figure Multilocular Cystic Clear Cell Renal Cell Carcinoma Examples
Table Key Downstream Customer in Multilocular Cystic Clear Cell Renal Cell Carcinoma
Figure Tubulocystic Renal Cell Carcinoma Examples
Table Key Downstream Customer in Tubulocystic Renal Cell Carcinoma
Figure Thyroid-Like Follicular Renal Cell Carcinoma Examples
Table Key Downstream Customer in Thyroid-Like Follicular Renal Cell Carcinoma
Figure Others Examples
Table Key Downstream Customer in Others
Figure United States Renal Cell Cacinoma Drugs Market Size (Million USD) by Region (2012-2022)
Figure The West Renal Cell Cacinoma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Renal Cell Cacinoma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Renal Cell Cacinoma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Renal Cell Cacinoma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Renal Cell Cacinoma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Renal Cell Cacinoma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Renal Cell Cacinoma Drugs Sales (K Pcs) and Growth Rate (2012-2022)
Figure United States Renal Cell Cacinoma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Renal Cell Cacinoma Drugs Market Major Players Product Sales Volume (K Pcs) (2012-2017)
Table United States Renal Cell Cacinoma Drugs Sales (K Pcs) of Key Players/Suppliers (2012-2017)
Table United States Renal Cell Cacinoma Drugs Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Renal Cell Cacinoma Drugs Sales Share by Players/Suppliers
Figure 2017 United States Renal Cell Cacinoma Drugs Sales Share by Players/Suppliers
Figure United States Renal Cell Cacinoma Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Renal Cell Cacinoma Drugs Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Renal Cell Cacinoma Drugs Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Renal Cell Cacinoma Drugs Revenue Share by Players/Suppliers
Figure 2017 United States Renal Cell Cacinoma Drugs Revenue Share by Players/Suppliers
Table United States Market Renal Cell Cacinoma Drugs Average Price (USD/Pcs) of Key Players/Suppliers (2012-2017)
Figure United States Market Renal Cell Cacinoma Drugs Average Price (USD/Pcs) of Key Players/Suppliers in 2016
Figure United States Renal Cell Cacinoma Drugs Market Share of Top 3 Players/Suppliers
Figure United States Renal Cell Cacinoma Drugs Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Renal Cell Cacinoma Drugs Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Renal Cell Cacinoma Drugs Product Category
Table United States Renal Cell Cacinoma Drugs Sales (K Pcs) by Region (2012-2017)
Table United States Renal Cell Cacinoma Drugs Sales Share by Region (2012-2017)
Figure United States Renal Cell Cacinoma Drugs Sales Share by Region (2012-2017)
Figure United States Renal Cell Cacinoma Drugs Sales Market Share by Region in 2016
Table United States Renal Cell Cacinoma Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Renal Cell Cacinoma Drugs Revenue Share by Region (2012-2017)
Figure United States Renal Cell Cacinoma Drugs Revenue Market Share by Region (2012-2017)
Figure United States Renal Cell Cacinoma Drugs Revenue Market Share by Region in 2016
Table United States Renal Cell Cacinoma Drugs Price (USD/Pcs) by Region (2012-2017)
Table United States Renal Cell Cacinoma Drugs Sales (K Pcs) by Type (2012-2017)
Table United States Renal Cell Cacinoma Drugs Sales Share by Type (2012-2017)
Figure United States Renal Cell Cacinoma Drugs Sales Share by Type (2012-2017)
Figure United States Renal Cell Cacinoma Drugs Sales Market Share by Type in 2016
Table United States Renal Cell Cacinoma Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Renal Cell Cacinoma Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Renal Cell Cacinoma Drugs by Type (2012-2017)
Figure Revenue Market Share of Renal Cell Cacinoma Drugs by Type in 2016
Table United States Renal Cell Cacinoma Drugs Price (USD/Pcs) by Types (2012-2017)
Figure United States Renal Cell Cacinoma Drugs Sales Growth Rate by Type (2012-2017)
Table United States Renal Cell Cacinoma Drugs Sales (K Pcs) by Application (2012-2017)
Table United States Renal Cell Cacinoma Drugs Sales Market Share by Application (2012-2017)
Figure United States Renal Cell Cacinoma Drugs Sales Market Share by Application (2012-2017)
Figure United States Renal Cell Cacinoma Drugs Sales Market Share by Application in 2016
Table United States Renal Cell Cacinoma Drugs Sales Growth Rate by Application (2012-2017)
Figure United States Renal Cell Cacinoma Drugs Sales Growth Rate by Application (2012-2017)
Table Merck & Co., Inc. Basic Information List
Table Merck & Co., Inc. Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Merck & Co., Inc. Renal Cell Cacinoma Drugs Sales Growth Rate (2012-2017)
Figure Merck & Co., Inc. Renal Cell Cacinoma Drugs Sales Market Share in United States (2012-2017)
Figure Merck & Co., Inc. Renal Cell Cacinoma Drugs Revenue Market Share in United States (2012-2017)
Table Exelixis Inc Basic Information List
Table Exelixis Inc Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Exelixis Inc Renal Cell Cacinoma Drugs Sales Growth Rate (2012-2017)
Figure Exelixis Inc Renal Cell Cacinoma Drugs Sales Market Share in United States (2012-2017)
Figure Exelixis Inc Renal Cell Cacinoma Drugs Revenue Market Share in United States (2012-2017)
Table Argus Therapeutics, Inc. Basic Information List
Table Argus Therapeutics, Inc. Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Argus Therapeutics, Inc. Renal Cell Cacinoma Drugs Sales Growth Rate (2012-2017)
Figure Argus Therapeutics, Inc. Renal Cell Cacinoma Drugs Sales Market Share in United States (2012-2017)
Figure Argus Therapeutics, Inc. Renal Cell Cacinoma Drugs Revenue Market Share in United States (2012-2017)
Table Bristol-Myers Squibb Basic Information List
Table Bristol-Myers Squibb Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Bristol-Myers Squibb Renal Cell Cacinoma Drugs Sales Growth Rate (2012-2017)
Figure Bristol-Myers Squibb Renal Cell Cacinoma Drugs Sales Market Share in United States (2012-2017)
Figure Bristol-Myers Squibb Renal Cell Cacinoma Drugs Revenue Market Share in United States (2012-2017)
Table Genentech Basic Information List
Table Genentech Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Genentech Renal Cell Cacinoma Drugs Sales Growth Rate (2012-2017)
Figure Genentech Renal Cell Cacinoma Drugs Sales Market Share in United States (2012-2017)
Figure Genentech Renal Cell Cacinoma Drugs Revenue Market Share in United States (2012-2017)
Table Immatics Biotechnologies Basic Information List
Table Immatics Biotechnologies Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Immatics Biotechnologies Renal Cell Cacinoma Drugs Sales Growth Rate (2012-2017)
Figure Immatics Biotechnologies Renal Cell Cacinoma Drugs Sales Market Share in United States (2012-2017)
Figure Immatics Biotechnologies Renal Cell Cacinoma Drugs Revenue Market Share in United States (2012-2017)
Table AVEO Oncology Basic Information List
Table AVEO Oncology Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure AVEO Oncology Renal Cell Cacinoma Drugs Sales Growth Rate (2012-2017)
Figure AVEO Oncology Renal Cell Cacinoma Drugs Sales Market Share in United States (2012-2017)
Figure AVEO Oncology Renal Cell Cacinoma Drugs Revenue Market Share in United States (2012-2017)
Table Eisai Basic Information List
Table Eisai Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Eisai Renal Cell Cacinoma Drugs Sales Growth Rate (2012-2017)
Figure Eisai Renal Cell Cacinoma Drugs Sales Market Share in United States (2012-2017)
Figure Eisai Renal Cell Cacinoma Drugs Revenue Market Share in United States (2012-2017)
Table Acceleron Basic Information List
Table Acceleron Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Acceleron Renal Cell Cacinoma Drugs Sales Growth Rate (2012-2017)
Figure Acceleron Renal Cell Cacinoma Drugs Sales Market Share in United States (2012-2017)
Figure Acceleron Renal Cell Cacinoma Drugs Revenue Market Share in United States (2012-2017)
Table Rexahn Pharmaceuticals Basic Information List
Table Rexahn Pharmaceuticals Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Rexahn Pharmaceuticals Renal Cell Cacinoma Drugs Sales Growth Rate (2012-2017)
Figure Rexahn Pharmaceuticals Renal Cell Cacinoma Drugs Sales Market Share in United States (2012-2017)
Figure Rexahn Pharmaceuticals Renal Cell Cacinoma Drugs Revenue Market Share in United States (2012-2017)
Table Bionomics Basic Information List
Table Cerulean Pharma Inc Basic Information List
Table Celldex Therapeutics Basic Information List
Table TVAX Biomedical Basic Information List
Table TRACON Pharmaceuticals Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Renal Cell Cacinoma Drugs
Figure Manufacturing Process Analysis of Renal Cell Cacinoma Drugs
Figure Renal Cell Cacinoma Drugs Industrial Chain Analysis
Table Raw Materials Sources of Renal Cell Cacinoma Drugs Major Players/Suppliers in 2016
Table Major Buyers of Renal Cell Cacinoma Drugs
Table Distributors/Traders List
Figure United States Renal Cell Cacinoma Drugs Sales Volume (K Pcs) and Growth Rate Forecast (2017-2022)
Figure United States Renal Cell Cacinoma Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Renal Cell Cacinoma Drugs Price (USD/Pcs) Trend Forecast (2017-2022)
Table United States Renal Cell Cacinoma Drugs Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Renal Cell Cacinoma Drugs Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Renal Cell Cacinoma Drugs Sales Volume (K Pcs) Forecast by Type in 2022
Table United States Renal Cell Cacinoma Drugs Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Renal Cell Cacinoma Drugs Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Renal Cell Cacinoma Drugs Sales Volume (K Pcs) Forecast by Application in 2022
Table United States Renal Cell Cacinoma Drugs Sales Volume (K Pcs) Forecast by Region (2017-2022)
Table United States Renal Cell Cacinoma Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Renal Cell Cacinoma Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Renal Cell Cacinoma Drugs Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

More Publications

Need Help?

Ask a Question

Market Reports

All Categories